Newsroom

Sorted by: Latest

-

Resumen: Signaloid se une al banco de pruebas de arquitecturas heterogéneas de CERN openlab para explorar el futuro de la informática científica

CAMBRIDGE, Inglaterra y GINEBRA--(BUSINESS WIRE)--La empresa británica de informática Signaloid se ha unido a CERN openlab, la asociación público-privada a través de la cual el CERN evalúa las tecnologías de la información emergentes para la informática científica. Como parte de esta colaboración, el CERN y Signaloid evaluarán la tecnología de hardware de computación de distribución ampliada (UxHw®) de Signaloid en el banco de pruebas de arquitecturas heterogéneas de CERN openlab, que explora n...
-

Samenvatting: Signaloid voegt zich bij het Heterogeneous Architectures Testbed van CERN openlab om de toekomst van wetenschappelijk gebruik van computers te verkennen

CAMBRIDGE, Engeland & GENEVE--(BUSINESS WIRE)--Het Britse computertechnologiebedrijf Signaloid voegt zich bij CERN openlab, de publiek-private samenwerking aan de hand waarvan CERN opkomende informatietechnologieën voor wetenschappelijk gebruik van computers evalueert. In het kader van de samenwerking zullen CERN en Signaloid de UxHw®-technologie (distribution-extended compute hardware) van Signaloid evalueren binnen het CERN openlab Heterogeneous Architectures Testbed, dat nieuwe processortech...
-

Signaloid rejoint le banc d’essai Heterogeneous Architectures du CERN openlab pour explorer l’avenir du calcul scientifique

CAMBRIDGE, Angleterre et GENÈVE--(BUSINESS WIRE)--La société informatique britannique Signaloid a rejoint le CERN openlab, le partenariat public-privé par lequel le CERN évalue les technologies de l’information émergentes pour le calcul scientifique. Dans le cadre de cette collaboration, le CERN et Signaloid évalueront la technologie de matériel de calcul à distribution étendue (UxHw®) de Signaloid au sein du banc d’essai des architectures hétérogènes du CERN openlab, qui explore de nouvelles t...
-

Riassunto: Signaloid partecipa al Heterogeneous Architectures Testbed di CERN openlab per esplorare il futuro del calcolo scientifico

CAMBRIDGE, Inghilterra e GINEVRA--(BUSINESS WIRE)--Signaloid, azienda britannica del settore informatico, è entrata a far parte di CERN openlab, la partnership pubblica-privata attraverso la quale il CERN valuta le tecnologie informatiche emergenti per il calcolo scientifico. Nell'ambito di questa collaborazione, CERN e Signaloid valuteranno la tecnologia hardware di calcolo a distribuzione estesa (UxHw®) di Signaloid all'interno del Heterogeneous Architectures Testbed di CERN openlab, che espl...
-

Signaloid tritt dem „Heterogeneous Architectures Testbed“ des CERN openlab bei, um die Zukunft des wissenschaftlichen Rechnens zu erforschen

CAMBRIDGE, England & GENF--(BUSINESS WIRE)--Das britische Computerunternehmen Signaloid ist dem CERN openlab beigetreten, einer öffentlich-privaten Partnerschaft, in deren Rahmen das CERN neue Informationstechnologien für das wissenschaftliche Rechnen evaluiert. Im Rahmen der Zusammenarbeit werden das CERN und Signaloid die Technologie „Distribution-Extended Compute Hardware“ (UxHw®) von Signaloid im „Heterogeneous Architectures Testbed“ des CERN openlab evaluieren, das neue Prozessortechnologi...
-

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on September 30, 2026. One individual was hired by Adicet in September 2026 and granted new hire non-qualified stock options to purchase 725 shares of Adicet’s common stock with an exe...
-

United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics’ patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).“We are pleased with the Co...
-

Foundation Marketing Helped Strengthen Bitly’s Position as a Top-Cited Brand in AI Search Through an Integrated GEO Program

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Foundation Marketing announced it has joined Profound's inaugural Agency Certification Cohort. Every Foundation engagement can now open with the same enterprise measurement that supported Bitly's continued growth as the most cited brand in its category. The certification recognizes agencies with proven expertise in measuring and improving how brands appear across generative AI platforms. Foundation is one of 18 agencies certified in the inaugural cohort. A...
-

Lifecore Biomedical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lifecore Biomedical, Inc. - LFCR

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Lifecore Biomedical, Inc. (NasdaqGS: LFCR) to Webster Equity Partners. Under the terms of the proposed transaction, shareholders of Lifecore will receive $6.28 in cash for each share of Lifecore that they own. KSF is seeking to determine whether this consideration and the process that led to it...
-

Doors Plus Consolidates Contact Centre and Store Operations on 8x8 Platform, Slashes Communications Costs by 50%

SYDNEY--(BUSINESS WIRE)--Doors Plus chooses the 8x8 Platform for CX by 8x8, Inc. (NASDAQ: EGHT) to standardise internal and customer communications, cutting costs by 50%...